Kintor Pharma Begins Patient Dosing In Phase III Trial Of Proxalutamide To Treat Male Patients With Mild/moderate Covid-19 Symptoms

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, announced that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate Covid-19 symptoms in the United States has completed the first patient enrollment and dosing.Dr. Xunwei Dong, chief medical officer of Kintor Pharmaceutical, commented, "Initiation of this phase III study of proxalutamide in male with mild or moderate Covid-19 symptoms in the US and other countries is a key milestone in fulfilling our mission to discover and develop effective therapies for Covid-19. We have been actively initiating MRCT phase III trials in the US, the EU, South Africa and South America including Brazil. We will keep close communications with the US FDA and other local regulatory authorities, and complete this pivotal study with high quality and efficiency."The phase III trial is a randomized, double-blind, placebo-controlled, multi-regional pivotal trial, designed to evaluate the efficacy and safety of proxalutamide in male outpatients with mild or moderate Covid-19 symptoms. The primary endpoint for the trial is the percentage of hospitalization events (including death) by Day 28. The secondary endpoints of the trial include but not limited to proportion of mortality by Day 28, percentage of patients achieving each clinical status on Days 7, 14 and 28 using National Institute of Allergy and Infectious Diseases (NIAID) 8-point scoring scale.Proxalutamide (GT-0918) is a nonsteroidal antiandrogen — specifically, a selective high-affinity silent antagonist of the androgen receptor — that is under development for the potential treatment of Covid-19, prostate cancer, and breast cancer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!